First-line treatment choice is driven by tumor molecular characterization, as patients with HER2 overexpressing/amplified GC (~17–20%) benefit from the addition of trastuzumab to the platinum/fluoropyrimidine chemotherapy backbone. Here, ERBB2 is linked to gastric cancer.